GSK-MSI Cervical Cancer Prevention Project

Partnership objectives 

Saving women’s lives through scaling-up cervical cancer prevention in least developed countries through promoting 5 key objectives:

  1. Advocacy: To support the development and/or implementation of national strategies for cervical prevention and control in the three proposed countries.  
  2. Awareness: To increase awareness among clients and service providers of the impact of cervical cancer and the availability of preventative services in the three countries.
  3. Screening and prevention: To introduce and/or enhance cervical cancer screening and preventative therapy services in the three proposed countries. 
  4. Organisational development: To strengthen MSI service providers’ knowledge & skills in cervical cancer prevention and treatment in the three countries. 
  5. Vaccination: To deliver HPV vaccination to girls (ages 9–13) in Bangladesh. As part of MSI’s wider cancer prevention advocacy efforts, MSI would seek to support GAVI demonstration vaccination pilot Sierra Leone and national scale up in Madagascar.

What are the health needs and challenges? 

Cervical cancer is the third most common cancer in women worldwide with 500,000 new cases and 250,000 deaths each year. The devastating impact of cervical cancer is disproportionately felt in developing countries where 80% of cases occur. 

Cervical cancer is both preventable and curable, with the HPV vaccine proving over 99% effective and forming the primary strategy for preventing cervical cancer. However, the lack of access to this vaccination and screening services in under-resourced developing countries makes women particularly vulnerable to Cervical cancer. 

Description of partnership activities and how they address needs and challenges 

The GSK-MSI partnership contributes to national efforts to reduce mortality through prevention and control of cervical cancer by advancing country level objectives in three of the world’s least developed countries; Bangladesh, Madagascar and Sierra Leone. 

The project in Bangladesh will provide 10,625 Cervical cancer screening services and 9,000 HPV vaccinations over 3 years, whilst creating a model for the future scale up of comprehensive cervical cancer prevention programmes and to facilitate policy dialogue at the national level. Similarly, in Madagascar, the partnership will promote awareness and work on advocacy whilst providing 34,000 Cervical cancer screening services and cryotherapy to 1,564 women. Finally, in Sierra Leone, screening services will be provided to 4,800 women during the 3 year project. These projects will follow WHO best practice on Cervical cancer prevention and take into account recommendations by GAVI. 

Summary of impact and forward looking information 

So far, a total of 5,647 women have been screened through the project, leading to 215 women receiving cryotherapy. 

The Partnership works alongside local and national health authorities to provide high quality services with a view to sustainability. Behaviour change communications will strengthen knowledge around Cervical cancer prevention and increase demand for services. Meanwhile, the capacity building of health providers will ensure the continued supply of screening and preventative therapy. 

Measurement of progress towards objectives:

  • Estimated amount of people impacted: ~50,000

Partnership information

Company(ies) GlaxoSmithKline

Partner(s) Marie Stopes International

Type of Partner(s) NGOs

Therapeutic Focus Non-Communicable Diseases, Women and Children's Health, Other

Disease(s) Adolescent Health, Cervical Cancer, Children's Health, General Health, Women's Health

Program Type(s) Health System Infrastructure - Outreach & Medical Services, Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach, Prevention Programs - Vaccines

Region(s) South Asia, Sub-Saharan Africa

Number of Countries 3

Country(ies) Bangladesh, Madagascar, Sierra Leone

Start Date 2015

Anticipated completion date 2018